• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, October 4, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Clinical trial shows promise for increasing lung transplant patients’ life expectancy

Bioengineer by Bioengineer
May 6, 2019
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results of a first-in-humans trial presented at AATS 99th Annual Meeting indicates the safety of a novel treatment for ischemia reperfusion injury where none has existed to-date

TORONTO – May 5, 2019 – A new study, presented today at the American Association for Thoracic Surgery’s 99th Annual Meeting, shows that a potential treatment for ischemia- reperfusion injury is safe for humans. Building upon three decades of preclinical animal studies, this NIH-funded trial demonstrated, for the first time, the safety of Regadenoson (an adenosine 2A receptor agonist) in human lung transplant patients.

Ischemia-reperfusion injury is a major source of morbidity and mortality in lung transplant patients, and contributes to the less than optimal survival rates in lung transplant recipients. Adenosine 2AR agonists like Regadenoson offer a potentially novel treatment for this common inflammatory complication where none exists today. Researchers found no dose limiting toxicities in the non-randomized trial and no 30-day mortality.

The TCV lab at University of Virginia, under the direction of Dr. Irving Kron, has spent three decades studying the efficacy of A2AR agonists for lung transplant in rodents and large animals.

In humans, Regadenoson, (LexiscanTM), is clinically approved as a bolus for myocardial imaging, but its safety profile in the high risk lung transplant population as an infusion had not been established. This clinical trial was designed to assess the safety of regadenoson in human lung transplant recipients as a prequel to an efficacy trial.

“It is gratifying to see this research move from bench to bedside, with decades of work culminating in a clinical trial,” said Senior Author, Dr. Christine Lau, Professor of Surgery in the Division of Thoracic & Cardiovascular Surgery at the University of Virginia. “As the field of lung transplants evolves rapidly, we continue to see ischemia-reperfusion injury, making the potential of a new treatment an exciting development.”

With safety established, the next step for testing efficacy is a multi-institutional, randomized trial. Additionally, because the treatment appears effective whether the drug is given to the donor lung or the recipient, future trials will use ex-vivo lung profusion to administer the drug only to the donor lung, eliminating any risk to the patient.

Presenting author Dr. Joshua A. Boys, MD explained, “This treatment has the potential to be the next big thing in the world of lung transplants. With further study, this can quickly move from a quality of life improvement therapy to one that greatly improves survival for the long term.”

###

Notes for Editors:

First in Human, Use of Regadenoson: An Adenosine 2A Receptor Agonist in Lung Transplant Recipients Christine L. Lau1, Jennifer V Phillips1, Michael J Cosner1, Mark R Conaway1, Gina R Petroni1, A. Sasha Krupnick1, Yunge Zhao1, Joel Linden2, Irving L Kron3

1 University of Virginia, Charlottesville, VA; 2 La Jolla Institute for Immunology, La Jolla, CA; 3 University of Arizona Health Sciences, Tucson, AZ

Presented by Joshua A. Boys, MD, Sunday, May 5, 2019 at the AATS 99th Annual Meeting.

ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)
The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit http://www.aats.org to learn more.

Media Contact
Alexis Merry
[email protected]

Tags: cancerClinical TrialsMedicine/HealthSurgeryTransplantation
Share13Tweet8Share2ShareShareShare2

Related Posts

Gut Microbiome and Hormones in Postmenopausal Breast Cancer

October 4, 2025
blank

α-L-Fucosidase Isoenzymes: New Glioma Prognostic Markers

October 4, 2025

Inflammatory Markers Shape EGFR-Mutant Lung Cancer

October 4, 2025

Radiomic Changes in Femur During Helical Tomotherapy

October 4, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    93 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    90 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    69 shares
    Share 28 Tweet 17

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Carers in Australia: Blessings and Challenges Explored

Gut Microbiome and Hormones in Postmenopausal Breast Cancer

Herbal Remedies for Hypertension: Insights from Trinidad

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.